- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03492827
Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESD
Backgrounds: With the continuous improvement of sterilization and endoscopic structure, the infection caused by endoscopy has gradually declined.With the rapid development of digestive endoscopic therapy in the past decade, therapeutic endoscopy has been widely carried out worldwide. These techniques have caused the mucous membrane or deeper damage to achieve the goal of curing the disease. During therapeutic endoscopic procedures, endogenous bacteria may be ectopic to the blood circulation due to mucosal or deeper damage. The endoscope is used to in and out lumens multiple times, and the injections are injected into the tissues through the accessories. These processes may bring the pathogenic bacteria from the patient's mouth into the digestive tract through the endoscope and enter the blood through the damaged mucosa. In addition, bacteremia associated with endoscopic procedures may cause bacterial infections in distant organs (eg infective endocarditis).
Postoperative infection rates can reach 12-22% . The results of the etiological culture show that it is consistent with the bacteria of oral bacteria. It is possibly related to multiple passage into the digestive tract of endoscopic and accessory . However, the endoscopic operation process will inevitably lead to subsequent infections.
ESD treatment involves endoscopic multiple access to the upper digestive tract through the mouth, attachments and injection needles and other multiple exposure to the wound, so the probability of postoperative infection is significantly higher than the average endoscope.
Investigators proposed to gargle patients with chlorhexidine acetate before ESD to improve the oral microenvironment and reduce the pathogenic bacteria in the oral cavity, so as to observe whether it can achieve the effect of preventing postoperative infection.
Methods and patients
- Objectives: This study is a prospective randomized controlled study in single center of Peking University Third Hospital. The purpose of the study is to evaluate the preventive effect of chlorhexidine acetate gargle on the infection of early upper gastrointestinal cancer after endoscopic ESD therapy.
- Calculation of sample size: According to the postoperative infection rate of 10%, 25% improvement is given after the gargle is administered, and the error range is calculated at 2%. The sample size needs 306 cases.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigator proposed to gargle patients with chlorhexidine acetate before ESD to improve the oral microenvironment and reduce the pathogenic bacteria in the oral cavity. The main purpose of the study is to evaluate the preventive effect of chlorhexidine acetate gargle on the infection of early upper gastrointestinal cancer after endoscopic ESD therapy.
Patients and Methods:
Patients:
Inclusion criteria:
- Diagnosis of early gastrointestinal cancer
- in line with endoscopic ESD treatment indications
- no limitation of age
Exclusion criteria:
- patients do not agree with the mouthwash
- The patient requested surgery
Methods
Screening and enrollment:
- Patients with early-stage upper gastrointestinal cancer diagnosed endoscopically in the ivestigator's hospital.
- ESD indications evaluation: endoscopic ultrasonography was used to assess the depth of lesion infiltration and surrounding lymph nodes. Abdominal or chest CT was used to further evaluate local lymph nodes and distant metastases.
- Patients with indications for treatment sign informed consent
Treatment programs:
- After the patient signed the informed consent, they will be divided into the experimental group and control group according to random envelopes in accordance with the sequence of patients were admitted. Patients in the treatment group are given twice daily three days before endoscopic treatment.Patients in the controlled group will not receive gargle.
- Treatment of second-generation cephalosporins or levofloxacin (allergic cephalosporins) intravenously half an hour before ESD procedure to prevent infection.
- The main steps of ESD include: marking around the lesion, submucosal injection to fully lift of the lesion, cutting the mucosa around the circumference, submucosal peeling to completely separate the submucosa and the muscularis propria to achieve a complete resection of the lesion, and checking the wound surface vessels and lesions.
- Monitor blood routine and body temperature changes on the first and third days after treatment. If there are signs of infection in the clinic, monitor PCT and add appropriate antibiotics.
Calculation of sample size: According to the postoperative infection rate of 10%, 25% improvement is given after the gargle is administered, and the error range is calculated at 2%. The sample size needs 306 cases.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Recruiting
- Peking University Third Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of early gastrointestinal cancer or high grade intraepithelial neoplasia
- In line with endoscopic ESD treatment indications
- No limitation of age
Exclusion Criteria:
- Patients do not agree with gargling
- The patient requested surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: gargle group
drugs,chlorhexidine acetate gargle dosage,15ml,twice daily, duration,3days before ESD
|
observe whether it can achieve the effect of preventing postoperative infection
|
|
No Intervention: Control group
Control group will not be interventioned with gargle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
infection rate 8 hours after ESD
Time Frame: 8 hours after ESD procedure
|
infection is defined as temperature is higher than 38.5℃,WBC is higher than 10000/mm3,PCT is higher than 0.5ng/ml
|
8 hours after ESD procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
infection rate 72 hours after ESD
Time Frame: 72 hours after ESD procedure
|
infection is defined as temperature is higher than 38.5℃,WBC is higher than 10000/mm3,PCT is higher than 0.5ng/ml
|
72 hours after ESD procedure
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
complications of ESD
Time Frame: within 7 days after ESD
|
bleeding,perforation
|
within 7 days after ESD
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yonghui Huang, MD, Peking University Third Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LM2017252
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterCompletedGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterCompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Lin LiuRecruitingGastric Carcinoma | Gastric Neoplasm | Gastric Cancer Adenocarcinoma Metastatic | Gastric (cardia, Body) CancerChina
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
-
Ukrainian Society of Clinical OncologyRecruitingGastric Cancer | Gastrectomy for Gastric Cancer | Gastric Cancer Stage III | Gastric Cancer Stage IIUkraine
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
Shanghai Changzheng HospitalNot yet recruitingGastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastric Cancer
Clinical Trials on chlorhexidine acetate gargle
-
Ataturk UniversityCompletedPost Operative Analgesia | Third Molar SurgeryTurkey (Türkiye)
-
Mundipharma Manufacturing Pte Ltd.Singapore Polytechnic (SP)Completed
-
University of Southern CaliforniaEnrolling by invitationDysphagia | Cervical Radiculopathy | Cervical Myelopathy | Cervical Spondylosis | Degeneration Spine | Cervical StenosisUnited States
-
Chang Gung Memorial HospitalNot yet recruitingHead and Neck Neoplasms | Chemoradiotherapy | Stomatitis and UlcerationTaiwan
-
Mayo ClinicCompletedVoice Disorders | Speech Therapy | Muscle Tension DysphoniaUnited States
-
Cairo UniversityUnknown
-
The University of Hong KongNot yet recruitingMaternal Infection During Pregnancy
-
Tufts UniversityNational Institute of Dental and Craniofacial Research (NIDCR)Completed
-
Dr Meru SCompletedOral Hygiene | pH | Saliva Altered | Tooth Structure; DisorderIndia
-
Sun Yat-sen UniversityRecruitingNasopharyngeal Cancinoma (NPC)China